DOI: 10.1161/circ.148.suppl_1.16530 ISSN: 0009-7322

Abstract 16530: Impact of Hyperuricemia on 5-year Clinical Outcomes in Patients With Critical Limb Ischemia Underwent Percutaneous Transluminal Angioplasty

Seong Joon An, Woo Jin Ahn, Byoung Geol Choi, Seung-Woon Rha, Se Yeon Choi, Jae Kyeong K Byun, Jinah Cha, Sujin Hyun, Soohyung Park, Dong Oh O Kang, Eun Jin J Park, Cheol Ung Choi
  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Background: A growing evidence on the correlation between hyperuricemia and cardiovascular disease (CVD) has been previously reported. However, there have been limited data on the impact of hyperuricemia on long-term clinical outcomes in patients with critical limb ischemia (CLI) who underwent percutaneous transluminal angioplasty (PTA).

Methods: A total, 425 peripheral artery disease (PAD) patients who underwent PTA for CLI were enrolled. The patients were divided into the hyperuricemia group (n=101) and the normal group (n=324). The primary endpoint was major adverse cerebral and cardiovascular event (MACCE), including death, myocardial infarction (MI), any coronary revascularization, and stroke, up to 5 years. The secondary endpoint was a major adverse limb event (MALE), including any repeated PTA, and target extremity surgery (TES). Inverse probability weighting (IPTW) analysis, derived from the logistic regression model, was performed to adjust for potential confounders.

Results: After IPTW matching analysis, compared to the normal group, the hyperuricemia group was associated with a higher incidence of MACCE (20.7% vs. 13.6%, hazard ratio [HR], 1.65; 95% confidence interval [CI], 1.15 - 2.38, p=0.006) including non-cardiac death (11.7% vs. 6.3%, HR: 1.95, 95% CI: 1.19 - 3.19, p=0.006) and MALE (47.7% vs. 36.0%, HR: 1.62, 95% CI: 1.23-2.13, p=0.001) including non-target extremity revascularization (TER) (15.0% vs. 6.8%, HR: 2.42, 95% CI: 1.52-3.84, P<0.001).

Conclusions: In the present study, hyperuricemia was associated with worse clinical outcomes in patients with CLI following PTA during 5-year clinical follow-up. Efficacy of controlling hyperuricemia in improving clinical outcomes should be evaluated in the further studies.

More from our Archive